MDCK-MRP2 - Dkfz

332
Forschungsschwerpunkt E
Innovative Krebsdiagnostik und -therapie
[77] Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A,
Strauss LG, Mäcke HR, Eisenhut M, Haberkorn U. Exceptional increase
of Somatostatin Receptor Expression in Pancreatic Neuroendocrine
Tumour, visualised with 68Ga-DOTATOC-PET. Eur J
Nucl Med 2004; 31:466.
Buchbeiträge
[78] Haberkorn U. Imaging Gene Expression. In: Wahl R (ed.)
Clinical Positron Emission Tomography: Principles and Practice.
Lippincott Williams and Wilkins Philadelphia: 2002; pp 420-430.
[79] Henze M. Chapter 1: Craniocerebral Diseases - Nuclear
Medicine Imaging. In: Diagnostic and Interventional
Neuroradiology - A Multimodality Approach (ed.) Sartor K, Georg
Thieme Verlag Stuttgart, New York 2002; pp 35-40.
[80] Henze M. Chapter 2: Spinal Diseases - Nuclear Medicine Imaging.
In: Diagnostic and Interventional Neuroradiology - A
Multimodality Approach (ed.) Sartor K, Georg Thieme Verlag
Stuttgart, New York 2002; pp 277-280.
[81] Haberkorn U. Positronenemissionstomographie. In: Drings
P, Dienemann H, Wannenmacher M (ed.). Management des
Lungenkarzinoms. Springer Verlag, Heidelberg; 2002; pp 125-
133.
[82] Schönknecht P, Pantel J, Hunt A, Henze M, Strowitzki T,
*Schröder J. Chapter 13: Estrogens in Alzheimer’s Disease: A
Clinical and Neurobiological Perspective. In: Estrogene Effects in
Psychiatric Disorders (Editors: Bergemann, Riecher-Rössler).
Springer Verlag, Berlin, Heidelberg, New York 2003, pp 259-276.
[83] Mattern J. Anticancer drug resistance: a multifactorial
problem. In: Mohan RM (ed.) Research Advances in Cancer. Global
Research Network, Kerala 2003, pp 275-281.
[84] Haberkorn U. Nuklearmedizinische Diagnostik von
Infektionen. In: Dommisch K, Lorenz D, Ekkernkamp A (ed.)
Chirurgie und Infektionen. Kaden Verlag Heidelberg: in press.
[85] Haberkorn U. Future clinical applications of PET (amino acid
and nucleoside imaging). In: Ell P, Gambhir S (ed.) Nuclear Medicine
in Clinical Diagnosis and Treatment, 3rd Ed: in press.
[86] Haberkorn U. Nuklearmedizinische Möglichkeiten in der
Primärdiagnostik und Follow up des Pleuramesothelioms. In: Das
Pleuramesotheliom (Hrsg. Manegold): in press.
[87] *Mier W, Hoffend J, Haberkorn U, Eisenhut M. Current
strategies in tumor-targeting. In: Gibson SB, Los M (eds).
Apoptotic Pathways as Targets for Novel Therapies in Cancer &
Other Diseases, Kluwer Academic Publ. Dordrecht, Boston, London:
2004, in press.
[88] Haberkorn U. Future directions in molecular imaging. In:
From morphological Imaging to Molecular Targeting. Ernst
Schering Workshop foundation. Volume 48: in press.
[89] *Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of
the closo-borane mercaptoundeca-hydrododecaborate (BSH) to
a tumour selective peptide. Z anorgan allgem Chemie 2004; 630
(8-9): 1258-1262.
[90] Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, *Mier
W, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma
cytotoxicity. Melanoma Res 2004; 14: 353-360.
[91] Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L,
Haberkorn U, Ewerbeck V, Thiesen HJ. F-18-FDG kinetics and
gene expression in giant cell tumors. J Nucl Med 2004; 45 (9):
1528-1535.
Abteilung E060
Klinische Kooperationseinheit Nuklearmedizin
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003